Delivery Order 36F79718D0566-36C26024F0506
Award Date 7/20/24
Potential Completion Date 9/30/24
Potential Value $33K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02142, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award, valued at $43,476.60, was issued by the Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract is a firm-fixed-price delivery order placed against Biogen's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract. The contract is for the delivery of QALSODY (tofersen), a pharmaceutical product used to treat neurological conditions in veterans. This award does not carry a...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm-fixed-price delivery order to Biogen U.S. Corporation, a pharmaceutical manufacturer, for the supply of QALSODY and QALSODY (TOFERSEN) 6.7MG SOLN. This $43,476.60 order was placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract and will be delivered by June 1, 2024. Biogen also holds a $11.39 million single-award indefinite delivery contract with the VA National Acquisition Center to provide...
- This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Biogen U.S. Corporation, a pharmaceutical manufacturer, for QALSODY (TOFERSEN) - EMERGENCY PHARMACY. The $21,738.30 firm-fixed-price order was placed against Biogen's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract, with no set-aside applied. The order will be performed in Cambridge, MA and is set to be completed by May 30, 2024. Biogen also holds a...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a $10,869.15 delivery order to Biogen U.S. Corporation under the company's Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule contract. The firm fixed price order is for QALSODY (TOFERSEN) 6.7MG SOLN NDC: 64406-0109-01, with an anticipated completion date of April 13, 2024. Place of performance will be in Cambridge, Massachusetts. No set-aside designation was used for this order....
- This is a federal contract award from the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological disorder treatments. The contract is a Delivery Order against Acorda's existing Federal Supply Schedule (FSS) contract with the VA, valued at over $16.3 million and expiring in September 2024. This specific award, valued at $861,948.00, is for the supply of DALFAMPRIDINE, a medication used to treat Parkinson's disease symptoms....
- This is a delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract is for the supply of Dalfampridine 10mg sustained-action (SA) tablets, a medication used to treat multiple sclerosis. The contract has a ceiling value of $485,835.00 and is a firm fixed-price delivery order, with no set-aside designation. This contract...
- The Department of Veterans Affairs (VA) Veterans Health Administration and Veterans Integrated Service Network 12 awarded a firm fixed price delivery order contract to Acorda Therapeutics, Inc., a biotechnology company that develops drugs to improve therapies for conditions such as multiple sclerosis, spinal cord injury, and Parkinson's disease. The contract, valued at $485,835.00, is for the delivery of DALFAMPRIDINE, a medication used to improve mobility in multiple sclerosis patients. This...
- This is a firm fixed-price delivery order contract awarded by the Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological therapies. The $861,948.00 contract is for the supply of DALFAMPRIDINE, a medication used to treat Parkinson's disease symptoms. The contract is placed under Acorda's Federal Supply Schedule (FSS) contract with the VA, which is valued at over $16.3 million and allows the VA to procure Acorda's pharmaceutical...
- This is a firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological therapies. The $478,860.00 contract is for the provision of DALFAMPRIDINE, which is likely a pharmaceutical product used to treat Parkinson's disease or multiple sclerosis. The delivery order was issued under Acorda's existing Federal Supply Schedule (FSS) contract with the VA, valued at over $16.3 million, for the...
- The Department of Veterans Affairs (VA) Veterans Health Administration and Veterans Integrated Service Network 12 awarded a firm fixed price delivery order contract to Acorda Therapeutics, Inc., a biotechnology company that develops drugs to improve therapies for neurological conditions. The $485,835.00 contract is for the delivery of DALFAMPRIDINE 10MG SA, a pharmaceutical product, with a completion date of July 14, 2017. The contract was issued off of the VA's Pharmaceuticals and Drugs Federal...